Interim analysis of Australian NASAR trial in seasonal allergic rhinitis shows statistically significant improvement with Bentrio® in nasal symptom primary endpoint over saline nasal spray comparator
NASAR main trial phase completed; full read-out expected in Q2 2023
Top line data from COVAMID trial in acute COVID-19 show trend for more pronounced reduction in nasal viral load and symptoms than no treatment, but primary endpoint not met
Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today provided an update on the clinical trials with Bentrio® in seasonal allergic rhinitis (SAR) and acute COVID-19. Bentrio nasal spray is intended to help protect against airborne allergens and viruses.
https://finance.yahoo.com/news/altamira-therapeutics-provides-clinical-trials-131700567.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.